Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives

Niccolò Bartalucci; Lorenzo Galluzzi

doi:10.1016/S1937-6448(22)00019-3

Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives

Int Rev Cell Mol Biol. 2022:366:ix-xx. doi: 10.1016/S1937-6448(22)00019-3.

Authors

Niccolò Bartalucci¹, Lorenzo Galluzzi²

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; DENOThe Excellence Center, University of Florence, Florence, Italy. Electronic address: niccolo.bartalucci@unifi.it.
² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, United States; Sandra and Edward Meyer Cancer Center, New York, NY, United States; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, United States; Department of Dermatology, Yale School of Medicine, New Haven, CT, United States; Université de Paris, Paris, France. Electronic address: deadoc80@gmail.com.

PMID: 35153008
DOI: 10.1016/S1937-6448(22)00019-3

No abstract available

Keywords: Calreticulin; Essential thrombocythemia; JAK2; Leukemic transformation; Myelofibrosis; Myeloproliferation; Polycythemia vera; Thrombopoietin receptor; Tyrosine kinase inhibitors.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Mutation
Myeloproliferative Disorders*
Neoplasms*